Rubraca® (Rucaparib) Approved in the U.S. as Monotherapy Treatment for Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Been Treated with Androgen Recept

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/4/2026

1. KRG
2. CCH:LN
3. META
4. CCHGY
5. PRY:IM
6. PRYMY
7. SPY
8. SKA-B
9. PBA
10. ALAR

Go back to Rubraca® (Rucaparib) Approved in the U.S. as Monotherapy Treatment for Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Been Treated with Androgen Recept
CLOVIS ONCOLOGY (NASDAQ: CLVS) Delayed: 0.08 --0 (-0%)
Previous Close $0.08    52 Week High $40.29 
Open $3.48    52 Week Low $11.57 
Day High $0.08    P/E N/A 
Day Low $0.08    EPS $-2.82 
Volume 282,973